Emergent BioSolutions Inc.EBSNYSE
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank95
3Y CAGR+149.0%
5Y CAGR+92.1%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+149.0%/yr
vs +32.0%/yr prior
5Y CAGR
+92.1%/yr
Recent acceleration
Acceleration
+116.9pp
Accelerating
Percentile
P95
Near historical high
vs 5Y Ago
26.2x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 3478.26% |
| Q3 2025 | -102.16% |
| Q2 2025 | 1050.00% |
| Q1 2025 | 85.98% |
| Q4 2024 | -151.98% |
| Q3 2024 | 223.58% |
| Q2 2024 | 175.88% |
| Q1 2024 | -295.02% |
| Q4 2023 | -46.50% |
| Q3 2023 | 152.45% |
| Q2 2023 | 37.83% |
| Q1 2023 | -298.28% |
| Q4 2022 | 225.41% |
| Q3 2022 | -374.36% |
| Q2 2022 | 58.18% |
| Q1 2022 | -111.34% |
| Q4 2021 | 1870.06% |
| Q3 2021 | 156.23% |
| Q2 2021 | -682.35% |
| Q1 2021 | -97.92% |
| Q4 2020 | 132.98% |
| Q3 2020 | -17.75% |
| Q2 2020 | 121.28% |
| Q1 2020 | -52.66% |
| Q4 2019 | 4038.71% |
| Q3 2019 | 91.34% |
| Q2 2019 | -134.16% |
| Q1 2019 | 163.22% |
| Q4 2018 | -195.28% |
| Q3 2018 | 403.07% |
| Q2 2018 | 3589.61% |
| Q1 2018 | -101.26% |
| Q4 2017 | 135.57% |
| Q3 2017 | -37.94% |
| Q2 2017 | 29.59% |
| Q1 2017 | 554.23% |
| Q4 2016 | -134.01% |
| Q3 2016 | 1377.37% |
| Q2 2016 | -105.59% |
| Q1 2016 | 1131.11% |